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AbstrACt 
Objectives To investigate the relative performance 
of knee replacement constructs compared with the 
best performing construct and illustrate the substantial 
variability in performance.
Design A non-inferiority study.
setting England and Wales.
Participants All primary total and unicondylar knee 
replacements performed and registered in the National 
Joint Registry between 1 April 2003 and 31 December 
2016.
Main outcome measures Kaplan-Meier failure function 
for knee replacement constructs. Failure difference 
between best performing construct (the benchmark) and 
other constructs.
Methods Using a non-inferiority analysis, the performance 
of knee replacement constructs by brand were compared 
with the best performing construct. Construct failure was 
estimated using the 1-Kaplan Meier method, that is, an 
estimate of net failure. The difference in failure between 
the contemporary benchmark construct and all other 
constructs were tested.
results Of the 449 different knee replacement constructs 
used, only 27 had ≥500 procedures at risk at 10 years 
postprimary, 18 of which were classified as inferior to the 
benchmark by at least 20% relative risk of failure. Two of 
these 18 were unicondylar constructs that were inferior by 
at least 100% relative risk. In men, aged 55–75 years, 12 
of 27 (44%) constructs were inferior by at least 20% to the 
benchmark at 7 years postprimary. In women, aged 55–75 
years, 8 of 32 (25%) constructs were inferior at 7 years 
postprimary. Very few constructs were classified as non-
inferior to the contemporary benchmark.
Conclusions There are few knee replacement 
constructs that can be shown to be non-inferior to a 
contemporary benchmark. Unicondylar knee constructs 
have, almost universally, at least 100% worse revision 
outcomes compared with the best performing total knee 
replacement. These results will help to inform patients, 
clinicians and commissioners when considering knee 
replacement surgery.
IntrODuCtIOn
Over 90 000 knee replacements are performed 
annually in England and Wales, and there 
is a bewildering choice of total and unicon-
dylar knee replacement (UKR) options avail-
able from which clinicians and patients can 
choose. When patients are considering a knee 
replacement, it is understandable that many 
assume that the different constructs function 
equally. However, all constructs are not equal 
as evidenced by variation in revision rates 
between brands and knee construct types.1 
The National Joint Registry for England, 
Wales, Northern Ireland and the Isle of Man 
(NJR) is the largest arthroplasty database in 
the world and publishes the unadjusted cumu-
lative failure rates of the most commonly 
used constructs in knee replacement surgery. 
This is a useful format for measuring absolute 
failure but does not allow easy head-to-head 
strengths and limitations of this study
 ► Data presented from the largest joint registry in the 
world.
 ► A novel and systematic comparison of the perfor-
mance of knee constructs to a contemporary bench-
mark knee construct.
 ► Unambiguous presentation of data will facilitate the 
consenting process for patients and allows surgeons 
and policy makers to be more informed with respect 
to success and failure of different constructs options 
available in knee replacement.
 ► Residual and unmeasured confounding factors are 
likely to be present.
 ► Potential for selection bias whereby certain con-
structs may be implanted for particular indications 
and in particular groups with different risks.
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comparison of constructs. Benchmarking bodies such 
as the Orthopaedic Device Evaluation Panel (ODEP) in 
the UK,2 NOV in the Netherlands3 and the Australian 
superior clinical performance programme4 compare 
construct performance against externally set benchmarks 
but do not perform head-to-head comparison. Although 
it is reassuring a certain standard has been met, this 
simple dichotomisation does not facilitate head-to-head 
comparison and the sample sizes used are arbitrarily set. 
Sayers et al5 recently proposed a method of comparison 
for joint replacement constructs using a non-inferiority 
design against an external benchmark. However, the 
primary limitation of this method remains the arbitrary 
requirement for an externally specified benchmark.
In a non-inferiority clinical trial,6 investigating failure, 
two treatments (comparator and reference) can be 
directly compared to ensure that the comparator treat-
ment is within a clinically acceptable range (non-infe-
riority margin) of performance at a specified point in 
time.7 8 Standard methods for assessing non-inferiority 
could be applied in an orthopaedic benchmarking 
setting, assuming an appropriate comparator, non-inferi-
ority margin and time of interest can be identified. This 
is a method we have applied in a medical device setting, 
namely, hip replacements using NJR data, in which we 
assessed the non-inferiority of hip replacement constructs 
as compared with a benchmark construct.9
Choosing an appropriate outcome and contemporary 
reference is difficult. There is no single outcome, no 
gold standard or evidence from randomised trials that 
suggests any construct outperforms all others; therefore, 
the choice is more heuristic. Patients would like to receive 
the best available care and clinicians would like to provide 
the best possible care, or at least care that is non-infe-
rior to the best. A binary, unambiguous, endpoint such 
as revision surgery represents one potential outcome of 
interest. Therefore, the natural choice of reference is the 
construct with the lowest failure rate. However, in order 
to protect against chance, the construct should be used 
in large enough numbers to mitigate sampling variability. 
The failure rate of a construct is influenced by both age 
and gender; therefore, the choice of reference should 
reflect this specificity. The selection of an appropriate 
time and non-inferiority margin to assess construct perfor-
mance is more subjective. For example, construct survi-
vorship in the long term is less relevant to older patients 
with shorter life expectancy, where improved quality of 
life, reduction in pain or improved physical functioning 
maybe more relevant.
The aim of this study is to investigate the relative perfor-
mance of knee replacement constructs as compared with 
the best performing contemporary construct, the bench-
mark, using a non-inferiority study design and to illus-
trate the substantial variability in performance of widely 
used constructs. This research focuses on total knee 
replacements (TKRs) and unicondylar knee replace-
ments (UKRs) as these are commonly used and therefore 
there is sufficient data to make robust comparisons. TKRs 
and UKRs are examined against non-inferiority margins 
of 20% relative risk and 100% relative risk at 3, 5, 7 and 10 
years following surgery. This is predicated on our belief 
that patients would at least want reassurance that the 
construct they are to receive is not estimated to be 100% 
worse than the best alternatives when used in patients 
with the same gender and age as them.
MethODs
Patients and data sources
We identified all patients with a primary TKR or 
UKR registered in the NJR between 1 April 2003 and 
31 December 2016. All patients were consented to be 
included in the NJR as part of the standard NJR process.
Procedures were excluded if the patient age or gender 
were missing, or the National Health Service number was 
untraceable and therefore mortality unknown. Proce-
dures where the constraint or fixation type were unknown 
were excluded from the analysis. Patellofemoral replace-
ments were also removed owing to the low number in the 
sample.
Brands of constructs are usually subdivided by fixation, 
mobility of the bearing and degree of constraint. NJR 
Annual Report data have shown that these characteristics 
influence revision rates, and thus, we treated each subdi-
vision as a separate construct.
Patient involvement
Patient representatives sit on the committee structure of 
the NJR. The research priorities of the NJR are identified 
by this committee structure and approved by the patient 
representatives. Patients were not involved in the setting 
of the research question or the outcome measures, nor 
were they involved in designing or implementing this 
work or interpretation of the results. We are unable to 
disseminate results of this study directly to study partici-
pants due to the anonymous nature of the data. We plan 
to disseminate our findings to the NJR, via their commu-
nications team, to consultations relevant to the provi-
sion of joint replacement and to the general population 
through the local and national press.
statistical methods
Using a non-inferiority analysis, the performance of knee 
constructs were compared with an internally identified 
benchmark group. Construct failure was estimated using 
the 1-Kaplan Meier method, that is, an estimate of net 
failure, which is appropriate when the risk of revision is 
considered.10
Failure is defined using the first linked surgical revi-
sion, where revision was defined as any addition, removal 
or modification of an implant to a joint that had previ-
ously undergone a TKR or UKR. Patients were censored 
at death or administratively censored on 31 December 
2016. The difference in stratum specific failure probabil-
ities compared with the benchmark were calculated at 3, 
5, 7 and 10 years for all constructs, stratified by gender, 
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and stratified by gender and age group (<55 years, 55–75 
years and >75 years).
The difference and 95% CI of the difference between 
the comparator construct and the benchmark construct 
was estimated at the specified time points. We used a 
95% CI, as is the convention in the majority of medical 
research. The SE of the difference was constructed using 
a pooled estimate of the Greenwood SE11
 
 
̂SE
(
Diff
)
=
√
GSE2xi + GSE
2
ref, 
 
and a z-test comparing the difference between the 
benchmark and test construct was then constructed using,
 
 
Z =
((
Fˆxi − Fˆref
)
+ δ
)
/̂SE
(
Diff
)
.
 
 
The stratum specific contemporaneous benchmark 
construct was selected as the knee construct (TKR or 
UKR) with the lowest failure rate with at least 1000 patients 
at risk at the time point of interest. The choice of 1000 
procedures of the same construct was based on simulation 
work by Sayers et al, which demonstrated that 1000 proce-
dures at risk will give rise to a CI width of approximately 
3% (±1.5%).5 We believe this is the minimal level of accu-
racy to be considered a suitable reference standard.
Two non-inferiority margins were chosen to illustrate 
the sensitivity of the choice. The first margin was conser-
vatively set at a 20% increase in relative risk of failure 
compared with the benchmark, in line with clinical trials 
using this methodology, although towards the upper 
end.12 The second was a 100% increase in relative risk, 
that is, a doubling in cumulative probability of failure, as 
this is an easily interpretable outcome.
Results are graphically reported for all comparator 
constructs with at least 500 patients still at risk at the 
beginning of the time point of interest. Results are also 
reported in a tabular format for all comparator constructs 
with at least 250 patients at risk at the beginning of the 
time point of interest (see online supplementary tables).
Constructs were either classified as non-inferior, incon-
clusive or inferior. If the upper CI is less than or equal to 
the 20% non-inferiority margin, the construct was non-in-
ferior. If the lower CI of the difference was greater than 
the non-inferiority margin at either 20% or 100%, the 
construct was classed as inferior at 20% or 100%, respec-
tively. If the lower confidence limit is less than the non-in-
feriority margin, and the upper confidence is greater than 
non-inferiority margin, the evidence against the construct 
was described as inconclusive (see figure 1 for graphical 
representation of the classification). All analyses were 
carried out using Stata V.15.1.
sensitivity analysis
We repeated all analyses using the best performing knee 
construct at 10 years with at least 1000 still at risk in the 
stratum of interest as the benchmark at the 3, 5 and 7 year 
time points.
results
There were 975 739 primary knee replacements included 
in the NJR between 1 April 2003 and 31 December 2016, 
using 649 different combinations of brand, fixation, 
constraint and bearing type. Following the application of 
the exclusion criteria (see online supplementary figure 
1), 947 686 procedures were included in the final analysis 
(863 551 [91.1%] TKRs), using 449 different combina-
tions of brand, fixation, constraint and bearing type (405 
TKRs and 44 UKRs).
A detailed description of non-inferiority across all proce-
dures is provided. Due to the large number of clinically 
Figure 1 Schematic representation of inferiority and non-inferiority.
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relevant subdivisions and sensitivity analyses, results will 
be described more broadly. Each stratification of age 
group, gender and time point of interest are provided in 
online supplementary material.
Constructs are described by brand, fixation, the degree 
of constraint for TKR and whether the bearing was fixed 
or mobile. Constraint types were either unconstrained 
(cruciate retaining) or posterior stabilised (posterior 
cruciate sacrificing). The vast majority of benchmark 
constructs were cemented. In each subdivision of our 
analyses, the construct that met our benchmark criteria 
was a TKR that was unconstrained with a fixed bearing. 
However, not all total knees that were unconstrained with 
fixed bearings performed well as there were 15 separate 
brands of this type that were found to be inferior to the 
benchmark by at least 20% relative risk in at least one 
subdivision analysis.
non-inferiority: all procedures
The benchmark construct at 3 years was identified as 
the NexGen cemented, unconstrained TKR with a fixed 
bearing. There were 34 558 procedures remaining at risk 
at 3 years for this construct, and the failure rate was 1.10% 
(95% CI 1.01 to 1.20). There were 73 constructs with ≥500 
procedures at risk. Thirty-nine constructs were classified 
as inferior to the benchmark by at least 20% relative risk 
of failure. Nine of the 73 were shown to be inferior by 
at least 100% relative risk (online supplementary figure 
2). One prosthesis, the NexGen TKR with a monobloc 
polyethylene tibia, was non-inferior. The remaining 32 
constructs were classified as non-inferiority not shown.
The benchmark construct at 5 years was identified as 
the Profix uncemented unconstrained TKR with a fixed 
bearing. There were 1910 procedures remaining at risk 
and the failure rate was 1.54% (95% CI 1.10 to 2.15). 
There were 65 constructs with ≥500 procedures at risk. 
Thirty-six were classified as inferior to the benchmark 
by at least 20% relative risk of failure. Twelve of the 36 
were shown to be inferior by at least 100% relative risk 
(figure 2). All of the UKRs with ≥500 procedures at risk 
(n=8) were inferior by at least 100% relative risk. No 
construct could be described as non-inferior.
The benchmark construct at 7 years was identified, 
again, as the Profix uncemented unconstrained TKR with 
a fixed bearing. There were 1501 procedures remaining 
at risk and the failure rate was 1.77% (95% CI 1.29 to 
2.43). There were 57 constructs with ≥500 procedures at 
risk. Thirty constructs were classified as inferior to the 
benchmark by at least 20% relative risk of failure. Eight 
of the 30 were shown to be inferior by at least 100% rela-
tive risk (online supplementary figure 3). All of the UKR 
constructs with ≥500 procedures at risk (n=5) were infe-
rior by at least 100% relative risk. No construct could be 
described as non-inferior.
The benchmark construct at 10 years was identified as 
the PFC Sigma Bicondylar Knee cemented unconstrained 
TKR with a fixed bearing. There were 19 284 procedures 
remaining at risk, and the failure rate was 2.37% (95% CI 
2.27 to 2.47). There were 27 constructs with ≥500 proce-
dures at risk. Eighteen constructs were classified as infe-
rior to the benchmark by at least 20% relative risk of 
failure. Two of the 18 were shown to be inferior by at least 
100% relative risk (figure 3). There were only two UKRs 
with ≥500 procedures at risk at 10 years, both of which 
were inferior to the benchmark by at least 100% relative 
Figure 2 Difference in cumulative revision of knee constructs compared with a contemporary benchmark at 5 years, using all 
total knee and unicondylar replacements with ≥500 procedures remaining at risk.
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risk. Two constructs were identified as non-inferior, the 
NexGen cemented unconstrained TKR with fixed bearing 
and the TKR PFC Sigma Bicondylar Knee hybrid unce-
mented with a fixed bearing.
Estimates for the difference in failure between the 
benchmark and comparator constructs with ≥250 proce-
dure at risk at the time of interest are shown in online 
supplementary tables 1–4.
non-inferiority: gender specific
Gender specific non-inferiority analyses were also 
performed at 3, 5, 7 and 10 years after the primary 
operation.
At 3 years, there were no constructs that demonstrated 
non-inferiority in comparison with the benchmark pros-
thesis. Most striking is the general similarity in constructs 
used and their performance regardless of gender. There 
were 56 different constructs with at least 500 procedures 
still at risk in women versus 50 in men. There were 25 
constructs with at least a 20% increase in relative risk in 
women versus 18 in men, although the increased number 
of inferior constructs demonstrated in women is likely 
owing to the slightly better performing benchmark group 
than in men. Three constructs were inferior by at least 
100% in men, each a UKR, and eight constructs were 
inferior by at least 100% in women (six UKRs and two 
TKRs).
At 5 years, in women, there were 49 constructs with ≥500 
procedures at risk. Twenty-nine of these constructs were 
classified as inferior to the benchmark by at least 20% 
relative risk of failure. Six of the 29 were shown to be 
inferior by at least 100% relative risk, four of which were 
UKRs. Similarly, in men, there were 43 constructs used 
with 19 inferior by at least a 20% increase in relative risk. 
Four of the 19 were inferior by at least 100% relative risk, 
all of which were UKRs. Results for men and women at 5 
years with ≥250 procedures at risk can be seen in tables 1 
and 2, respectively.
At 7 years, the results were again similar between men 
and women. There were 40 different constructs used 
in women and 36 in men. In women, there were 19 
constructs that were inferior by at least 20% relative risk, 
two of which were inferior by at least 100%. These were 
both UKRs. In men, 18 of the 36 constructs with ≥500 
procedures still at risk were deemed to be inferior to the 
benchmark by at least 20% relative risk. Three of these 
18 were inferior by at least 100% relative risk, all of which 
were UKRs. Two constructs were demonstrated to be 
non-inferior to the benchmark.
At 10 years, in both men and women, there was only 
one brand of UKR that had at least 500 procedures still at 
risk. In both instances, this was inferior by at least 100% 
relative risk and was the only construct to be classified 
as such. There were no brands found to be non-inferior 
to the benchmark in either men and women. In women, 
there were 8 of 15 constructs that were inferior to the 
benchmark by at least 20% relative risk. In men, 8 out of 
13 constructs that were inferior to the benchmark by at 
least 20% relative risk. Data for gender specific stratifica-
tion can be viewed in online supplementary figures 4, 5, 
6 and 7 for men at 3, 5, 7 and 10 years, respectively, and 
online supplementary figures 8, 9, 10 and 11 for women 
at 3, 5, 7 and 10 years, respectively.
non-inferiority: gender and age specific
Subdividing procedures by age and gender highlights 
the paucity of information available for male or female 
patients <55 years compared with those ≥55 years. There 
is little data at 7 years, and no suitable benchmark could 
be found for women at 10 years in the <55 age group. 
There is a similar mix of construct types in each of the age 
groups in both men and women with cemented uncon-
strained TKRs with a fixed bearing the most popular type. 
Data for men under 55 years of age at 3, 5 and 7 years 
can be viewed in online supplementary figures 12, 13 and 
14, respectively. Data for women under 55 years of age at 
Figure 3 Difference in cumulative revision of knee constructs compared with a contemporary benchmark at 10 years, using all 
total knee and unicondylar replacements with ≥500 procedures remaining at risk.
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3, 5 and 7 years can be viewed in online supplementary 
figures 15, 16 and 17, respectively.
At 7 years in women aged 55–75 years, there were 32 
different constructs that met the threshold of 500 cases 
for analysis with 8 being classified as inferior by at least 
20% relative risk (figure 4). Two of these were inferior 
by at least 100% relative risk and both were UKRs. No 
constructs were demonstrated to be non-inferior to the 
benchmark. In men, there were 27 constructs meeting 
the threshold with 12 being classified as inferior by at 
least 20% relative risk (figure 5). A single prosthesis, 
1 of the 2 UKRs with at least 500 procedures still at 
risk, was classified as being inferior by at least 100% 
relative risk. One construct was found to be non-infe-
rior to the benchmark. Data for men between 55 years 
and 75 years of age at 3, 5 and 10 years postprimary 
can be viewed in online supplementary figures 18, 19 
and 20, respectively. Data for women between 55 years 
and 75 years of age at 3, 5 and 10 years postprimary can 
be viewed in online supplementary figures 21,22 and 
23, respectively.
In the >75 years age group, we found only one inferior 
construct in both men and women at 7 years. Non-infe-
riority was not shown for any other prostheses, but very 
few met the threshold of 500 cases needed for analysis. At 
10 years, only three constructs with ≥500 procedures still 
at risk were present in men and five in women. Non-in-
feriority was not demonstrated in any of these. At this 
time point and age group subdivision, there were no 
UKRs with enough procedures still at risk to be included 
in the analysis. Data for men >75 years of age at 3, 5, 7 
and 10 years postprimary can be viewed in online supple-
mentary figures 24, 25, 26 and 27, respectively. Data for 
women >75 years of age at 3, 5, 7 and 10 years postprimary 
can be viewed in online supplementary figures 28, 29, 30 
and 31, respectively.
Data for each level of stratification for comparator 
constructs with at least 250 patients at risk at the begin-
ning of the time point of interest can be viewed in the 
following supplemental tables. Data for all men at 3, 7 
and 10 years can be seen in online supplemental tables 
5, 6 and 7, respectively, and for all women at 3, 7 and 10 
years in online supplemental tables 8, 9 and 10. Data for 
men <55 years of age at 3, 5 and 7 years can be seen in 
online supplemental tables 11, 12 and 13, respectively, 
and women <55 at 3, 5 and 7 years can be seen in online 
supplemental tables 14, 15 and 16, respectively. Data for 
men aged between 55 years and 75 years at 3, 5, 7 and 
10 years can be seen in online supplemental tables 17, 
18, 19 and 20, respectively, and for women aged between 
55 years and 75 years at 3, 5, 7 and 10 years data can 
be seen in online supplemental tables 21, 22, 23 and 
24, respectively. Data for men aged >75 years at 3, 5, 7 
and 10 years postprimary can be seen in online supple-
mental tables 25, 26, 27 and 28, respectively, and for 
women >75 years at 3, 5, 7 and 10 years postprimary data 
can be seen in online supplemental tables 29, 30, 31 and 
32, respectively.K
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sensitivity analysis
Using the benchmark construct at 10 years as the bench-
mark at 3, 5 and 7 years illustrates the temporal improve-
ments in failure and the selective trajectory tracking of 
new constructs. The benchmark construct in all proce-
dures at 10 years is the PFC Sigma Bicondylar Knee 
cemented unconstrained TKR with a fixed bearing that 
had a failure rate of 2.37% (95% CI 2.27 to 2.47). At 3, 5 
and 7 years, the contemporary benchmark has a 0.15%, 
a 0.17% and 0.23% lower point-estimate failure rate than 
the historical benchmark, respectively. The performance 
of the constructs appears to track in a consistent manner 
from each time point to the next.
DIsCussIOn
We have demonstrated, in 947 686 primary TKRs and 
UKRs, the relative performance of knee constructs in 
comparison with an internally selected relevant contem-
porary benchmark. There are two striking findings from 
the data analysed here. First, UKR brands almost univer-
sally have 100% worse revision outcomes in all ages, 
gender and time points of interest compared with the 
benchmark standard brand of knee replacement. Second, 
very few brands of knee replacement can be proven not to 
be at least 20% worse than the benchmark brands despite 
449 brand constructs having been implanted in England 
and Wales since 2003. Between one-third and two-thirds 
of the knee constructs for which sufficient data were 
available at each time point were at least 20% inferior 
to the contemporary benchmark. The vast majority of 
constructs are implanted in too few cases to allow mean-
ingful analysis. Many of those implanted in sufficient 
number have here been demonstrated to be inferior in 
terms of construct survivorship, while very few TKRs have 
been demonstrated to be non-inferior to a contemporary 
benchmark.
It is known that TKRs as a class have lower revision rates 
than UKRs, which poses the question, should these two 
classes be directly compared? Since every patient who 
received a UKR could have received a TKR instead, this 
comparison is justified. There is no evidence to suggest 
that the subsequent observed revision rates would be any 
different if those receiving a UKR had received a TKR 
instead. Furthermore, ODEP (currently) do not provide 
a rating for UKRs so this method provides extra transpar-
ency and previously unavailable information for patients 
undergoing knee replacement.
Comparison with other studies and implications in light of 
existing evidence
No other published study has performed a direct head-
to-head comparison of all available knee replacement 
constructs. The closest available data are from national 
registry annual reports such as the NJR,1 which reports 
absolute failure of the most common constructs by age 
and gender. This shows that low failure rates are achieved 
by a number of constructs, but this does not facilitate K
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easy direct comparison between them. Using the data 
presented here alongside the annual report data will 
greatly enhance the information available to surgeons, 
commissioners and to inform patient choice.
Consideration of the difference in outcome of UKR 
compared with TKR is complex. Using propensity score 
matching of registry data, Liddle et al13 showed that 
UKRs have higher revision rates than TKRs but lower 
risks of complications. Hunt et al and Liddle et al showed 
UKRs to be associated with lower early postoperative 
mortality.13 14 Kleeblad et al15 performed a systematic 
review and meta-analysis of 49 cohort studies and found 
no difference in function as measured by Hospital for 
Special Surgery Score, Knee Society Score, Oxford Knee 
Score, Visual Analog Pain Scale and Western Ontario and 
McMaster Universities Osteoarthritis Index Score but 
did show higher revision rates with UKRs. Liddle et al16 
also showed no clinically important difference in Oxford 
Knee Scores (one point difference favouring UKR), but 
UKR patients were more likely to be highly satisfied 6 
months after surgery. A recent study by the same group 
has shown that UKR is less costly than TKR particularly in 
older patients, who are less likely to require revision, and 
when performed by higher volume surgeons.17 Our data 
add to this complex picture by clearly demonstrating the 
increased risk of revision associated with almost all brands 
Figure 4 Difference in cumulative revision of knee constructs compared with a contemporary benchmark at 7 years in women 
aged between 55 years and 75 years, using all total knee and unicondylar replacements with ≥500 procedures remaining at risk.
Figure 5 Difference in cumulative revision of knee constructs compared with a contemporary benchmark at 7 years in men 
aged between 55 years and 75 years, using all total knee and unicondylar replacements with ≥500 procedures remaining at risk.
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of UKRs at all time points in both genders and all age 
groups when compared with the best performing TKRs.
The major weakness of all registry studies is selec-
tion bias whereby certain constructs may be implanted 
for particular indications and in particular groups with 
different risks. We have mitigated against this by analysing 
data by age and gender, the two variables with the greatest 
association with revision rates. Furthermore, revision 
thresholds may be lower in certain groups or for certain 
modes of failure. This study has looked at a single, but 
extremely important, outcome measure: revision. Other 
outcomes of interest such as mortality and patient-report 
outcome measures need to be considered when making 
choices about treatment. With over 900 000 subjects, this 
is the largest study of knee replacement published to date 
and comes from the largest implant registry in the world. 
Data entry is mandated, and data capture is extremely 
high (over 95%),18 thus the findings are highly likely to 
be generalisable. The methods used are novel and, for 
the first time, allow a meaningfully direct comparison 
between all available constructs.
Conclusions, policy and future research implications
The use of product benchmarking has the potential to 
be highly informative for patients, change the practice of 
surgeons and influence policy makers if presented clearly 
and unambiguously. The implications of this research are 
far reaching. We are unable to definitively state which 
construct is the best choice for all patients, due to the 
presence of selection effects and residual confounding. 
However, we believe that the information presented here 
illustrates the variability, frequency and performance of 
different constructs currently used in clinical practice 
which, in turn, should be used to further inform the 
consenting process between the patient and the surgeon 
and facilitate implant selection. We believe commis-
sioners and policy makers should consider the variability 
and performance of different implants in the commis-
sioning of healthcare providers.
Patients should be actively involved in decision making 
about their treatment. Here we provide, for the first time, 
data that allow patients and clinicians to directly compare 
revision rates associated with the use of different UKR 
and TKR constructs. The information provided should be 
used to inform patient choice, surgical decision making 
and commissioning.
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